Evidence map›Paper›PMID 22484909›Full record

ArticleJournal of neuro-oncology2012

Overactivation of Ras signaling pathway in CD133+ MPNST cells.

Emma Borrego-Diaz, Kaoru Terai, Kristina Lialyte, Amanda L Wise, Tuba Esfandyari, Fariba Behbod, Victor F Mautner, Melanie Spyra, Sarah Taylor, Luis F Parada and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. RalA is overactivated in medulloblastoma.Journal of neuro-oncology · 2016
    Article
  6. Review
  7. Article
  8. CD133: a stem cell biomarker and beyond.Experimental hematology & oncology · 2013
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Emma Borrego-DiazKUMC-Molecular Medicine Laboratory, Department of Medicine, The University of Kansas Medical Center, Kansas city, KS 66160, USA.
Kaoru Terai
Kristina Lialyte
Amanda L Wise
Tuba Esfandyari
Fariba Behbod
Victor F Mautner
Melanie Spyra
Sarah Taylor
Luis F Parada
Meena Upadhyaya
Faris Farassati
University of Kansas Medical Center · USCardiff University · GBThe University of Texas Southwestern Medical Center · USUniversität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Kansas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) are believed to be the regenerative pool of cells responsible for repopulating tumors. Gaining knowledge about the signaling characteristics of CSCs is important for understanding the biology of tumors and developing novel anti-cancer therapies. We have identified a subpopulation of cells positive for CD133 (a CSC marker) from human primary malignant peripheral nerve sheath tumor (MPNST) cells which were absent in non-malignant Schwann cells. CD133 was also found to be expressed in human tissue samples and mouse MPNST cells. CD133+ cells were capable of forming spheres in non-adherent/serum-free conditions. The activation levels of Ras and its downstream effectors such as ERK, JNK, PI3K, p38K, and RalA were significantly increased in this population. Moreover, the CD133+ cells showed enhanced invasiveness which was linked to the increased expression of β-Catenin and Snail, two important proteins involved in the epithelial to mesenchymal transition, and Paxilin, a focal adhesion protein. Among other important characteristics of the CD133+ population, endoplasmic reticulum stress marker IRE1α was decreased, implying the potential sensitivity of CD133+ to the accumulation of unfolded proteins. Apoptotic indicators seemed to be unchanged in CD133+ cells when compared to the wild (unsorted) cells. Finally, in order to test the possibility of targeting CD133+ MPNST cells with Ras pathway pharmacological inhibitors, we exposed these cells to an ERK inhibitor. The wild population was more sensitive to inhibition of proliferation by this inhibitor as compared with the CD133+ cells supporting previous studies observing enhanced chemoresistance of these cells.

Indexed as

Signal TransductionAC133 AntigenAnimalsAntigens, CDApoptosisCell DifferentiationCell Line, TumorCell ProliferationEndoplasmic Reticulum StressFlow CytometryGlycoproteinsHumansImmunophenotypingMiceNeoplasm InvasivenessNeoplastic Stem CellsAC133 AntigenAntigens, CDGlycoproteinsPeptidesPROM1 protein, humanProm1 protein, mouseras Proteins

Identifiers

PMID22484909
OpenAlexW2063049154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.